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Allogeneic hematopoietic stem cell transplantation (HSCT) can achieve durable remissions in a number of
patients with advanced hematologic malignancies. Little is known about the safety of HSCT in patients age 70
or older. Consecutive patients (n ¼ 54) age 70 or older underwent HSCT between 2007 and 2012. Diseases
included acute myelogenous leukemia (n ¼ 25), myelodysplastic syndrome (n ¼ 12), chronic lymphocytic
leukemia (n ¼ 5), non-Hodgkin lymphoma (n ¼ 4), acute lymphoblastic leukemia (n ¼ 3), myeloproliferative
neoplasm (n ¼ 4), and chronic myelogenous leukemia (n ¼ 1). Median follow-up for survivors was 21 months.
All patients received reduced-intensity conditioning regimens, primarily busulfan/ﬂudarabine. All patients
received unmanipulated peripheral blood stem cell grafts: 44 from 8/8 matched unrelated donors, 8 from
matched related donors, and 2 from 7/8 matched unrelated donors. Graft-versus-host disease (GVHD)
prophylaxis was calcineurin inhibitorebased in all patients. The median age at transplantation was 71 years
(range, 70 to 76); the median HCT comorbidity index score was 1 (range, 0 to 5). Two patients died before
hematopoietic recovery (1 with graft failure and 1 with disease progression), and 1 patient relapsed before
hematopoietic recovery; otherwise, all engrafted with median donor chimerism of 94% at 1 month. Cumu-
lative incidence of grades II to IV acute GVHD was 13% and of grades III to IV acute GVHD, 9.3%. At 2 years, the
cumulative incidence of chronic GVHD was 36%, progression-free survival was 39%, overall survival was 39%,
and relapse was 56%. Nonrelapse mortality was 3.7% at day þ100 and 5.6% at 2 years. We conclude that
allogeneic HSCT is a safe and effective option for carefully selected patients age 70 or older.
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Hematologicmalignancies aremore common among older
patients. This age group has historically had worse outcomes
when compared with younger counterparts [1,2]. Allogeneic
hematopoietic stem cell transplantation (HSCT) can achieve
durable remissions in a number of patients with advanced
hematologic malignancies, but its application to the elderly
has been traditionally limited by arbitrary age restrictions
[1,2], reﬂecting concerns of high rates of nonrelapsemortality
(NRM) and morbidity with traditional myeloablative regi-
mens [3-5]. The advent of reduced-intensity conditioning
(RIC) regimens has extended HSCT to increasingly older
adults [6-8].
Despite the success of RIC, the number of potential
patients over the age of 50 that undergo HSCTafter remission
is low, estimated at only 14% of patients in 1 analysis [9]. In
most analyses investigating risk factors to predict NRM after
HSCT, if other comorbidities are appropriately taken into
account, older age has not been shown to be a signiﬁcant
factor [8,10,11], challenging the concept of an arbitrary upper
age limit for consideration of allogeneic transplantation.edgments on page 1379.
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The purpose of the current study is to describe our institu-
tions’ outcomes for patients age 70 or older undergoing HSCT
for advanced hematologic diseases.
METHODS
Patients
We identiﬁed 54 consecutive patients age 70 or older who underwent
allogeneic HSCT at Massachusetts General Hospital (n ¼ 14) or the Dana-
Farber Cancer Institute (n ¼ 40) between January 1, 2007 and July 11,
2012. Inclusion criteria included all patients who underwent allogeneic
HSCT for a hematologic disease as long as patients were age 70 or older on
the day of transplantation. This study was approved by the institutional
review board of the Dana-Farber/Harvard Cancer Center. Eligibility for
transplantation, conditioning regimens, and supportive care were similar in
the 2 centers and have been described previously [12,13].
Deﬁnitions
Diagnoses were classiﬁed according to the World Health Organization
system. HCT comorbidity index scores were calculated as described by
Sorror et al. [14]. Disease risk index (DRI) scoreswere calculated as described
by Armand et al. [15]. Patients with myelodysplastic syndrome (MDS) and
acute myelogenous leukemia (AML) had cytogenetic risk documented as
described by the National Cancer Research Institute Adult Leukemia
Working Group [16]. Only RIC regimens were administered, which were
consistent with a previously described consensus classiﬁcation [17].
The primary outcomes were relapse, NRM, overall survival (OS), and
progression-free survival (PFS). NRM was deﬁned as any cause of death
occurring after transplantation without documented relapse. Relapse was
deﬁned as relapse with or without death. PFS was deﬁned as the time from
stem cell infusion until the date of relapse or death, whichever occurredTransplantation.
Table 1
Baseline Characteristics
Characteristic N Percent
Age, y, median (range) 71 (70 to 76)
Donor age, y, median (range) 33 (18 to 74)
Patient sex
Male 36 66.7
Female 18 33.3
Donor type
Matched related donor (8/8) 8 14.8
Matched unrelated donor (8/8) 44 81.5
Matched unrelated donor (7/8) 2 3.7
Disease
AML 25 46.3
MDS 12 22.2
ALL 3 5.6
NHL 4 7.4
CML 1 1.9
CLL 5 9.3
MPN 4 7.4
Cytogenetic risk (of patients with AML or MDS)*
Favorable 1 1.9
Intermediate 19 35.2
Adverse 17 31.5
ECOG performance status
0 10 18.5
1 30 63.0
2 10 18.5
HCT comorbidity index
0 20 37
1 11 20.4
2 6 11.1
3 6 11.1
4 6 11.1
5 5 9.3
Median (range) 1 (0 to 5)
Conditioning regimen
Busulfan 3.2 mg/kg and ﬂudarabine 28 51.9
Busulfan 6.4 mg/kg and ﬂudarabine 23 42.6
Fludarabine/melphalan 2 3.7
Clofarabine/ATG/total lymphoid irradiation 1 1.9
DRI score
0 (low) 5 31.5
1 (intermediate) 24 1.9
2 (high) 20 35.2
3 (very high) 5 31.5
Recipient CMV status
Positive 29 53.7
Negative/equivocal 25 46.3
GVHD prophylaxis
CNI þ MTX 9 16.7
CNI þ sirolimus  MTX 34 63
CNI þ mycophenolate mofetil 1 1.9
CNI þ ATG þ MTX 7 13
Other 3 5.6
Number of rehospitalizations, median (range) 1 (0 to 11)
ALL indicates acute lymphocytic leukemia; NHL, non-Hodgkin lymphoma;
CML, chronic myeloid leukemia; CLL, chronic lymphocytic leukemia; MPN,
myeloproliferative neoplasm; CMV, cytomegalovirus; CNI, calcineurin
inhibitor; MTX, methotrexate; ATG, antithymocyte globulin.
* Patients with AML or MDS were categorized by favorable risk, inter-
mediate risk, or adverse risk cytogenetic proﬁles using karyotype at diag-
nosis [16].
Table 2
Disease Status at Time of Transplantation
Disease n (%) Disease Status at Transplantation (n)
AML 25 (46%) CR1 (17), CR2 (3), CR3 (1), induction failure (2),
untreated (2)
MDS 12 (22%) PR (1), refractory (6), untreated (5)
ALL 3 (6%) CR1 (2), CR2 (1)
NHL 4 (7%) DLBCL in PR (1), relapsed DLBCL (1), T cell
lymphoma (2)
CML 1 (2%) Blastic phase in remission (1)
CLL 5 (9%) PR (2), CR (1), relapse (1), persistent T cell CLL (1)
MPN 4 (7%) MPN/MDS overlap, failed chemotherapy (1);
CMML in remission (1) or failed chemotherapy (1);
myeloﬁbrosis, failed chemotherapy (1)
ALL indicates acute lymphocytic leukemia; NHL, non-Hodgkin lymphoma;
CML, chronic myeloid leukemia; CLL, chronic lymphocytic leukemia; MPN,
myeloproliferative neoplasm; PR, partial remission; DLBCL, diffuse large
B-cell lymphoma; CMML, chronic myelomonocytic leukemia.
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Patients who were alive at the time of our analysis were censored at the last
known alive date.
Neutrophil engraftment was deﬁned as the ﬁrst day of an absolute
neutrophil count >500/mL on 3 consecutive measurements. Platelet
recovery was deﬁned as the ﬁrst day of 2 consecutive measurements of
>20,000/mL without transfusion support in the prior 72 hours. All patients
received calcineurin inhibitorebased regimens (most commonly tacroli-
mus) as graft-versus-host disease (GVHD) prophylaxis. In general, taper of
immune suppressionwas initiated 3 to 4months after transplantation in the
absence of active GVHD, with the goal of immunosuppression cessation by
approximately 6 to 8 months after HSCT. No pre-emptive or planned
prophylactic donor lymphocyte infusions were given. Acute GVHD (aGVHD)was graded by consensus grading criteria [18], and chronic GVHD (cGVHD)
was deﬁned clinically by treating physicians. Grading of the severity of
cGVHD was not included in this analysis given the changes in classiﬁcation
schemes during the period these patients were treated [19,20].
Statistical Analysis
Descriptive statistics were used to summarize patient baseline charac-
teristics. Cumulative incidences of GVHD, relapse, and NRM were estimated
in the competing risks framework. Cumulative incidence of GVHD was
constructed considering death or relapse as competing risks. Cumulative
incidences of NRM and relapse were constructed considering relapse for
NRM and NRM for relapse as a competing risk. OS and PFS were estimated
using the method of Kaplan-Meier, with 95% conﬁdence intervals (CIs)
calculated using Greenwood’s formula. Kaplan-Meier curveswere compared
using the log-rank test, and cumulative incidence curves were compared
using the Gray test [21]. Potential prognostic factors for OS, PFS, and relapse
were examined using the proportional hazards model for OS and PFS and
the Fine and Gray model [22] for cumulative incidence of relapse. All
P values are 2-sided with a signiﬁcance level of .05. All statistical analyses
were performed using SAS 9.2 (SAS Institute, Cary, NC) and R version 2.13.2
(R Foundation for Statistical Computing, Vienna, Austria).
RESULTS
Patient Characteristics
Patient characteristics are summarized in Table 1. This
was the ﬁrst allogeneic HSCT for all patients except one. The
median age at transplantation was 71 years old (range, 70 to
76). The median follow-up for survivors was 21 months
(range, 7 to 55). There was a slight male predominance (67%).
Prior cytomegalovirus antibodies were detected in 29 of 54
recipients.
Diagnoses varied, with the most common being AML and
MDS (Table 2). Among patients with AML, most (84%) were in
complete remission (CR) (21 of 25 patients: 17 in CR1, 3 in
CR2, 1 in CR3). Of the 12 patients with MDS, 1 was in partial
remission, 6 had refractory disease, and 5 were untreated. Of
the 37 patients with AML or MDS, 17 (46%) had adverse
cytogenetic risk. Six of 10 with adverse risk AMLwere in CR1,
2 had failed induction, and 2 were untreated. One of 7 with
adverse risk MDS was in partial remission, 3 had refractory
disease, and 3 were untreated. The 3 patients with acute
lymphocytic leukemia were in CR1 (n ¼ 2) or CR2 (n ¼ 1).
Patients with non-Hodgkin lymphoma consisted of 2
patients with diffuse large B-cell lymphoma (DLBCL) and 2
patients with T cell lymphoma. One patient had blast-phase
chronic myeloid leukemia in CR, and 5 patients had chronic
lymphocytic leukemia. Patients with myeloproliferative
neoplasms consisted of 1 patient who had a myeloprolifera-
tive neoplasm/MDS overlap syndrome, 2 patients with
chronic myelomonocytic leukemia (CMML), and 1 patient
with myeloﬁbrosis.
Table 3
Summary of Survival and GVHD Outcomes (n ¼ 54)
Day 100 (95% CI) 6 Mo (95% CI) 1 Yr (95% CI) 2 Yrs (95% CI)
OS, % 49 (36 to 62) 39 (25 to 53)
PFS, % 39 (26 to 51) 39 (26 to 51)
Cumulative incidence of NRM, % 3.7 (.7 to 11.4) 5.6 (1.4 to 14.0) 5.6 (1.4 to 14.0) 5.6 (1.4 to 14.0)
Cumulative incidence of relapse, % 55.6 (41 to 68) 55.6 (41 to 68)
Grades II-IV aGVHD 13 (5.6 to 23)
Grades III-IV aGVHD 9.3 (3.4 to 19)
All cGVHD 34 (22 to 47) 36 (23 to 49)
Extensive cGVHD 22 (12 to 34) 24 (14 to 37)
OS and PFS were calculated by the method of Kaplan andMeier. The cumulative incidence of NRM, relapse, and GVHDwere calculated using the competing risks
method. Both aGVHD and cGVHD were assessed using consensus criteria.
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risk by calculation of the HCT comorbidity index [14,23]; the
median score was 1 (range, 0 to 5). Most had an HCT
comorbidity index score of 0 (n ¼ 20) or 1 (n ¼ 11), but
a number had higher scores of 2 (n ¼ 6), 3 (n ¼ 6), 4 (n ¼ 6),
and 5 (n¼ 5). All patients with HCT comorbidity index scores
of 5 had moderate (n ¼ 4) or severe (n ¼ 1) pulmonary
disease, and 3 had a prior solid tumor. Because a number of
different hematologic conditions were considered in this
analysis, we also calculated the DRI group for each patient
[15]. Most patients fell into the intermediate risk (n ¼ 24,
44.4%) or high risk (n ¼ 20, 37.0%) DRI groups, although
10 patients (18.6%) were categorized as low (n ¼ 5) or very
high-risk (n ¼ 5) DRI groups.Transplantation and Donor Characteristics
Most patients received a conditioning regimen containing
intravenous busulfan, at a total dose of either 3.2 mg/kg
(n ¼ 28) or 6.4 mg/kg (n ¼ 23) and ﬂudarabine, dosed at
120 mg/m2 total (94% of patients) [12,24]. Two patients
received a combination of melphalan at 140 mg/m2 and
ﬂudarabine. One patient was enrolled in an institutional
clinical trial and received a combination of clofarabine,
antithymocyte globulin, and total lymphocyte irradiation.
The choice of conditioning regimenwas based on institution
norm, physician choice, and enrollment in speciﬁc clinical
trials.
All patients received peripheral blood stem cells. Most
patients (44/54, or 82%) received stem cells from an 8/8 HLA
matched unrelated donor. Eight patients (15%) received an 8/
8 matched related donor transplantation, whereas 2 patients
(4%) received stem cells from a 7/8 matched unrelated donor.
The median matched related donor age was 63.5 years.
For GVHD prophylaxis, most patients received a combi-
nation of tacrolimus and sirolimus  mini-methotrexate
(5 mg/m2 per dose) (34/54 patients, 63%) [13]. A small
number of patients received tacrolimus and mini-
methotrexate alone (9/54 patients, 17%) or antithymocyte
globulin in combination with tacrolimus and methotrexate
(7/54 patients, 13%).Figure 1. Cumulative incidence of (A) acute and (B) chronic GVHD. (A) The
cumulative incidence of grades II to IV aGVHD is shown in red, whereas grades
III to IV acute GVHD are in blue. (B) The cumulative incidence of all cGVHD is
shown as a red line; extensive cGVHD is in blue. These analyses were per-
formed using death and relapse as competing risks. (A color version of this
ﬁgure can be seen at www.bbmt.org.)Engraftment
Of the 54 patients in this study, 2 patients died before
engraftment: 1 patient with CMML from graft failure and
1 patient with AML from disease progression. One patient
relapsed before engraftment. All other patients achieved
neutrophil and platelet engraftment. Of the 43 patients who
experienced a neutrophil nadir <500/mL, the median time to
neutrophil engraftment was 13 days (range, 2 to 31 days).
The median time to platelet engraftment was 17 days (range,3 to 83 days) among the 40 patients whose absolute platelet
count dropped to <20,000/mL.
Chimerism was measured by standard short tandem
repeat (STR) genotyping analysis, and the median all-cell
donor chimerism among 51 patients who engrafted was
94% (range, 36% to 100%) at day 30; 84% (43/51) achieved
80% all-cell donor chimerism by 1 month after HSCT.
Median all-cell donor chimerismwas 94% among 39 patients
who had ameasurement at a subsequent time point near day
100 (range, 0% to 100%). Sustained chimerism (deﬁned as
day-30 total leukocyte chimerism 80% and day 100 80%)
A.M. Brunner et al. / Biol Blood Marrow Transplant 19 (2013) 1374e1380 1377was seen in 28 of 39 patients and was associated with
improved OS (mortality hazard ratio [HR], .34; 95% CI, .14 to
.83, P ¼ .018), PFS (HR, .21; 95% CI, .09 to .49, P ¼ .0003), and
lower risk of relapse (HR, .19; 95% CI, .07 to .51, P ¼ .001).Graft versus Host Disease
The cumulative incidence of grades II to IV aGVHD was
13% at 200 days (Table 3, Figure 1A), whereas the cumulative
incidence of grades III to IV aGVHD was 9.3%. The cumulative
incidence of cGVHD was 34% at 1 year and 36% at 2 years
after transplantation (Table 3, Figure 1B). The cumulative
incidence of extensive cGVHD was 22% at 1 year and 24% at
2 years.Survival Outcomes
The cumulative incidence of relapse at 2 years was 55.6%.
NRM was 3.7% at 100 days and 5.6% at 2 years (Table 3,
Figure 2). There were 4 patient deaths without relapse of
disease: 1 patient with CMML failed to engraft and died from
complications of graft failure on dayþ29; 1 patient with AML
died from sepsis on day þ64; 1 patient with MDS died from
complications of dementia, believed to be age-related and
not due to the transplantation, on day þ1163; and 1 patient
with MDS died from complications from aGVHD on
day þ158. OS and PFS rates at 1 year were 49% and 39%,
respectively, and at 2 years were 39% and 39%, respectively
(Table 3, Figure 3).
Of the 32 patients who relapsed, 4 developed cGVHD
during their follow-up period; this occurred after relapse in 3
of these 4 patients. One patient with AML relapsed on
day þ105; he developed cGVHD during immunosuppression
taper and recovered donor chimerism to 98% but subse-
quently died from Serratia marcescens septicemia on
day þ268. The second patient had AML and relapsed on
day þ142; he developed cGVHD during immunosuppression
taper with count recovery. He maintained remission until
day þ637 when he relapsed again; immunosuppression
taper and a donor lymphocyte infusion were attempted but
were unsuccessful, and he subsequently died from AML on
day þ680. The third patient had MDS, relapsed on day þ162,
and developed cGVHD in the setting of immunosuppression
taper; a donor lymphocyte infusion was performed but was
unsuccessful, and the patient died on day þ258. EighteenFigure 2. Cumulative incidence of NRM (red) and relapse (blue). Each was
treated as a competing risk in this analysis. (A color version of this ﬁgure can
be seen at www.bbmt.org.)
Figure 3. Kaplan-Meier estimates of OS and PFS. (A) Survival curves for all
patients. OS is shown in red, whereas PFS is shown in blue. Hash marks
indicate times at which patients are censored from the analysis. (B and C)
Patients with AML or MDS that had either favorable or intermediate risk
cytogenetics (red line) had improved OS (P¼ .045) and PFS (P¼ .016) compared
with patients with adverse risk cytogenetics (blue line) or other disease (green
line). (A color version of this ﬁgure can be seen at www.bbmt.org.)patients are alive and relapse-free, of whom 15 developed
cGVHD. Four patients died from NRM as described previ-
ously; the patient who died from complications of dementia
had developed cGVHD before death.
Table 4
Summary of Survival Outcomes by Risk Group
OS PFS Cumulative Incidence of Relapse
Risk Group 1 Yr (95% CI) 2 Yrs (95% CI) 1 Yr (95% CI) 2 Yrs (95% CI) 1 Yr (95% CI) 2 Yrs (95% CI)
AML/MDS with favorable/intermediate
cytogenetics
75 (50 to 89) 53 (25 to 75) 60 (36 to 78) 60 (36 to 78) 35 (15 to 56) 35 (15 to 56)
AML/MDS with adverse cytogenetics or
other disease
34 (19 to 50) 30 (16 to 46) 26 (13 to 42) 26 (13 to 42) 68 (49 to 81) 68 (49 to 81)
P Value .045 .016 .02
Patients with AML orMDS who had favorable or intermediate cytogenetic risk had an improved OS, PFS, and lower cumulative incidence of relapse at both 1 and
2 years after transplantation compared with patients who had either adverse cytogenetics or other diseases. Because the outcomes of patients with adverse risk
AML/MDS were similar compared with patients with other disease, these 2 categories are collapsed for the interest of power.
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We performed a univariable analysis to identify prog-
nostic factors for OS, PFS, and relapse. Because the rate of
NRM was very low, we did not evaluate predictors for NRM.
For patients with MDS and AML, the OS and PFS rates were
signiﬁcantly longer for patients with favorable/intermediate
cytogenetics compared with patients with unfavorable
cytogenetics or with other disease (2-year OS: 53% versus
30%, respectively, P ¼ .045; 1-year PFS: 60% versus 26%,
respectively, P ¼ .016) (Table 4, Figure 3B, C). Univariable Cox
regression analysis showed that patients with favorable/
intermediate cytogenetic risk AML/MDS had a decreased HR
for mortality (HR, .47; 95% CI, .22 to 1.002, P ¼ .051) and for
disease progression (HR, .41; 95% CI, .19 to .87, P ¼ .02). The
cumulative incidence of relapse for AML/MDS patients with
favorable/intermediate cytogenetics was signiﬁcantly lower
compared with patients with unfavorable cytogenetics or
other diseases (2-year cumulative incidence of relapse: 35%
versus 68%, P ¼ .02 using Gray test; HR, .4; 95% CI, .19 to .85,
P ¼ .017 from the Fine and Gray model).
For all patients, busulfan dose (3.2 versus 6.4 mg/kg) did
not appear to be associated with differences in OS (HR, .96;
95% CI, .48 to 1.90, P ¼ .90), PFS (HR, 1.15; 95% CI, .59 to 2.27,
P ¼ .68), or relapse (HR, 1.16; 95% CI, .58 to 2.32, P ¼ .67). Age,
gender, donor type (matched unrelated donor versus
matched related donor), GVHD prophylaxis, cytomegalovirus
positivity, and HCT comorbidity index score were not
signiﬁcant predictors for OS, PFS, or relapse in the uni-
variable analysis (data not shown). Very high DRI score was
signiﬁcant for predicting poor OS (HR, 5.84; P ¼ .04) but not
relapse (HR, 3.02; P ¼ .29) due largely to the small sample
size in this group (n ¼ 5). An ECOG (Eastern Cooperative
Oncology Group) score of 2was associatedwith an HR of 2.98
for mortality compared with an ECOG score of 0 (95% CI, 1.02
to 8.75; P¼ .046) but was not associated with worse PFS (HR,
2.13; 95% CI, .77 to 5.90, P ¼ .15) or relapse (HR, 1.24; 95% CI,
.42 to 3.63, P ¼ .70). There was no signiﬁcant difference in
outcomes between patients with an ECOG score of 1 and an
ECOG score of 0. A multivariable model could not be ﬁt to the
data given the number of variables.
Rehospitalizations
We evaluated the number of rehospitalizations after HSCT
for each patient based on discharge summary information
collected from the medical record, which includes hospitals
afﬁliated with Partners HealthCare, Boston, Massachusetts.
This does not account for hospitalizations outside of the
Partners network and did not include emergency depart-
ment or clinic visits. The median number of all-cause
rehospitalizations (including for disease relapse) was
1 rehospitalization during the follow-up period (range, 0 to
11). Nineteen of 53 patients (36%) who survived beyond theinitial transplantation admission never required rehospital-
ization. The median number of rehospitalizations for all
patients within 6 months was 0 (range, 0 to 2), and the
median number of rehospitalizations for all patients within
1 year was 1 (range, 0 to 7).
DISCUSSION
The burden of hematologicmalignancies is highest among
elderly patients, who, for multiple reasons, also have worse
outcomes [1,2]. Allogeneic HSCT using RIC regimens may
offer improved survival and lower rates of relapse compared
with other therapies [4,6,10,12,25-27]. In this retrospective
analysis, we report our experience with HSCT for 54
consecutive patients over the age of 70 from 2007 to 2012.
Based on our results, we conclude that HSCT appears to be an
effective and tolerable option for carefully selected adults
over the age of 70, with an encouragingly low cumulative
incidence of NRM of 5.6% at 1 year, as well as a 2-year PFS of
39% and 2-year OS of 39%. Among patients in this cohort who
underwent transplantation for MDS or AML (68% of this
cohort), we found that the presence of favorable/interme-
diate risk cytogenetics was associated with superior
outcomes, speciﬁcally 1-year PFS of 75% and 1-year OS of 60%.
Increasingly, it appears that RIC HSCT is successful in
carefully selected elderly cohorts with a variety of hemato-
logic malignancies. A large study performed by the Center for
International Blood &Marrow Transplant Research (CIBMTR)
studied patients older than age 40 undergoing RIC HSCT,
which included 63 patients with AML and 55 patients with
MDS older than age 65 [11]. In that study, which included
patients up to age 79, age did not appear to adversely affect
NRM, relapse, disease-free survival, or OS. This was also
described in a prior series of patients older than age 60
treated with RIC regimens at the Dana-Farber Cancer Insti-
tute [12]. Patients older than age 65 (range, 65 to 71) at
transplantation did no worse than those age 60 to 65 in
terms of NRM, relapse, OS, or PFS, a ﬁnding conﬁrmed in
a similar retrospective study of 600 patients from France
[28]. Previously, the largest reported series of HSCT over age
70 consisted of 33 patients treated at the Fred Hutchinson
Cancer Research Center [29]. That study included patients
treated between 1998 and 2008 and reported that, for this
age group, the 5-year cumulative incidence of NRM was 31%,
and relapse was 42%; 5-year OS was 25% and PFS was 27%.
This current study adds to the literature by reporting
survival outcomes in the largest series of patients older than
age 70 that underwent transplantation with current regi-
mens. Our results are similar to those previously reported for
patients older than age 60, treated at the same institution
between 2002 and 2008 with similar conditioning regimens
and GVHD prophylaxis [12]. In that study, the cumulative
incidence of relapse and NRM at 2 years was 54.6% and 10%,
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respectively. In addition, in that study, OS and PFS at 2 years
were 46% and 35%, respectively; in the current analysis, we
report 2-year OS and PFS rates of 39% and 39%. Of note,
2 patients in the current study were included in that prior
analysis but, given this small number, are unlikely to signif-
icantly inﬂuence our conclusions.
Inherent in this type of analysis is the selection of ﬁt
patients deemed eligible for HSCT by practicing physicians.
Most of our cohort had HCT comorbidity index scores of 2 or
less, although 17 patients (31%) had scores of 3 or above.
Although the HCT comorbidity index score did not seem to
correlate with OS in our analysis, the rate of NRMwas so low
(5.6% at 1 year) that it is difﬁcult to make ﬁrm conclusions.
What appears to be clear is that transplantation physicians
can safely select candidate patients who are ﬁt for HSCT, even
among patients over 70 years of age.
Given the retrospective nature of the analysis, the
heterogeneous patient population selected for trans-
plantation, and the referral patterns at our institutions, there
is no control arm of comparably age patients who either
were deemed not ﬁt for HSCT or were treated with alterna-
tive therapies. Thus, we are unable to assess whether HSCT
improved the prognosis of such patients. Insight into which
elderly patients are most likely to beneﬁt from HSCT is
limited by the heterogeneity of underlying hematologic
diseases we included. More patients in this cohort had AML
or MDS, relative to other hematologic malignancies, likely
because of the lack of suitable alternative therapies for these
diseases particularly in this elderly patient population.
Nevertheless, most of our patients were in advanced risk
categories as classiﬁed by the DRI and thus would have
generally poor outcomes with conventional treatment.
Previous comparisons suggest a beneﬁt for HSCT in elderly
patients with MDS and AML [30-32]. For instance, 1 study
compared RIC HSCT with azacitidine treatment in patients
with MDS; those who underwent transplantation had an
improvement in survival after 2 years [25]. Another study
compared the results of HSCT from the CIBMTR with
consecutive cohorts of AML patients age 60 or older receiving
chemotherapy-based treatment on CALGB (Cancer and
Leukemia Group B) protocols and found reduced relapse
rates and increased leukemia-free survival with HSCT [32].
Most recently, a multicenter study coordinated by the CALGB
and Bone Marrow Transplant Clinical Trials Network (BMT
CTN) illustrated the impressive results of RIC HSCT for
patients age 60 or older (range, 60 to 74) with AML in CR1
treated with uniform conditioning and GVHD prophylaxis
regimens. Results showed a 2-year OS rate of 46% along with
relatively low rates of TRM and GVHD [33].
It is most notable that the incidence of both NRM and
aGVHD were low in our cohort of patients. The observed rate
of grades II to IV and III to IV aGVHD is comparable with our
previously described RIC cohorts [12,13,33,34]. Our observed
low incidence of NRM and aGVHD in this elderly group likely
reﬂects effective patient selection. As seen with most RIC
cohorts, disease relapse and associated subsequent mortality
remain the most common cause for failure and the biggest
challenge for successful long-term disease management.
cGVHD was more common among patients who were alive
and relapse-free; only one patient relapsed after developing
cGVHD.
Further follow-up is needed in larger patient cohorts to
determine if physicians can accurately predict which
patients truly beneﬁt from allogeneic transplantation andwhich are at the highest risk for NRM. Patients with AML or
MDS who had favorable or intermediate cytogenetics
appeared to have better outcomes in our study; however,
further interpretations are limited by heterogeneity both of
this subgroup and of the entire cohort. The poorer outcomes
seen within those patients with adverse risk cytogenetics is
an area for further study; this group may beneﬁt from more
intensive pre and posttransplantation interventions, such as
alternative therapies before HSCT and prophylactic donor
lymphocyte infusions or other interventions after HSCT, to
try to harness an effective graft-versus-leukemia effect.
Additionally, most transplantations were matched unrelated
donors, which was likely because many in our cohort did not
have eligible siblings or their treating physician chose not to
use a sibling donor due to the sibling’s age. A study is
currently in progress through the CIBMTR registry to simi-
larly describe the characteristics and outcomes of patients
over the age of 70 undergoing HSCT that will provide a larger
cohort from which to learn. Finally, future studies will also
have to focus on other more qualitative outcomes such as
cost-effectiveness and quality of life, because various
complications may be much more expensive and difﬁcult to
treat in older patients relative to younger counterparts.
The biggest challenge of performing HSCT in the elderly
population may, in fact, be the hesitance or reluctance of
oncologists to refer older patients for consideration for HSCT.
One study from the M.D. Anderson Cancer Center showed
that even after instituting an “automatic transplantation
consultation” program for patients over age 50 with AML or
high-risk MDS, few patients eventually underwent trans-
plantation: only 53 of 99 eligible patients had a trans-
plantation evaluation, and only 14 of those patients
eventually proceeded to transplantation [9]. Clearly, despite
increasing data suggesting safety and beneﬁt of RIC trans-
plantation regimens in elderly patients, HSCT remains an
underused treatment in this population. Studies like ours,
which demonstrate encouraging tolerability and effective-
ness in highly selected elderly patients, will hopefully
increase awareness of, and thus access to, HSCT for this
patient population. When treating patients age 70 and over
with a reasonable performance status and comorbidity
proﬁle, age alone should not preclude referral for trans-
plantation consultation and consideration for allogeneic
HSCT.
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